within Pharmacolibrary.Drugs.ATC.L;

model L03AX19
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L03AX19</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Dasiprotimut-T is a therapeutic cancer vaccine consisting of a pool of seven synthetic peptides derived from tumor-associated antigens (TAAs) conjugated to keyhole limpet hemocyanin and mixed with Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as an adjuvant. It has been primarily investigated for use in melanoma as an immunotherapeutic agent. It is not approved for general clinical use at this time and remains in clinical trial investigations.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic (PK) parameters have been reported in the literature for dasiprotimut-T in any specific population or setting, as is typical for vaccine-based immunotherapies composed of peptides and adjuvants.</p><h4>References</h4><ol><li><p>Liu, L (2018). Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. <i>Protein &amp; cell</i> 9(1) 15–32. DOI:<a href=\"https://doi.org/10.1007/s13238-017-0408-4\">10.1007/s13238-017-0408-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28421387/\">https://pubmed.ncbi.nlm.nih.gov/28421387</a></p></li><li><p>Lugo, RA, &amp; Kern, SE (2002). Clinical pharmacokinetics of morphine. <i>Journal of pain &amp; palliative care pharmacotherapy</i> 16(4) 5–18. DOI:<a href=\"https://doi.org/10.1080/j354v16n04_02\">10.1080/j354v16n04_02</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/14635822/\">https://pubmed.ncbi.nlm.nih.gov/14635822</a></p></li><li><p>Wang, W, et al., &amp; Balthasar, JP (2008). Monoclonal antibody pharmacokinetics and pharmacodynamics. <i>Clinical pharmacology and therapeutics</i> 84(5) 548–558. DOI:<a href=\"https://doi.org/10.1038/clpt.2008.170\">10.1038/clpt.2008.170</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18784655/\">https://pubmed.ncbi.nlm.nih.gov/18784655</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L03AX19;
